High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Cysteine‐reactive small molecules are used as chemical probes of biological systems and as medicines. Identifying high‐quality covalent ligands requires comprehensive kinetic analysis to distinguish selective binders from pan‐reactive compounds. Quantitative irreversible tethering (qIT), a general method for screening cysteine‐reactive small molecules based upon the maximization of kinetic selectivity, is described. This method was applied prospectively to discover covalent fragments that target the clinically important cell cycle regulator Cdk2. Crystal structures of the inhibitor complexes validate the approach and guide further optimization. The power of this technique is highlighted by the identification of a Cdk2‐selective allosteric (type IV) kinase inhibitor whose novel mode‐of‐action could be exploited therapeutically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, the quantitative irreversible tethering (qIT) method has been reported for screening PPI covalent inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [82]
In the citing paper
“Thus, the FTQ can be a simple and cost-effective assay for screening covalent inhibitors of PPIs.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Hein, J. E., & Fokin, V. V. (2010) · Chemical Society Reviews · doi:10.1039/b904091a · Cited by 2,198
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Fluorescent and colorimetric probes for detection of thiols
Chen, X., Zhou, Y., Peng, X., & Yoon, J. (2010) · Chemical Society Reviews · doi:10.1039/b925092a · Cited by 1,580
A ‘Rule of Three’ for fragment-based lead discovery?
Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,354
Proteome-wide covalent ligand discovery in native biological systems
Backus, K. M., Correia, B. E., Lum, K. M., Forli, S., Horning, B. D., González-Páez, G. E., Chatterjee, S., Lanning, B. R., Teijaro, J. R., Olson, A. J., et al. (2016) · Nature · doi:10.1038/nature18002 · Cited by 940
Fragment-Based Approaches in Drug Discovery and Chemical Biology
Scott, D. E., Coyne, A. G., Hudson, S. A., & Abell, C. (2012) · Biochemistry · doi:10.1021/bi3005126 · Cited by 460
Tethering: Fragment-Based Drug Discovery
Erlanson, D. A., Wells, J. A., & Braisted, A. C. (2004) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.biophys.33.110502.140409 · Cited by 385
Flanagan, M. E., Abramite, J. A., Anderson, D. P., Aulabaugh, A., Dahal, U. P., Gilbert, A. M., Li, C., Montgomery, J., Oppenheimer, S. R., Ryder, T., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501412a · Cited by 320
Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer
Bar-Peled, L., Kemper, E. K., Suciu, R. M., Vinogradova, E. V., Backus, K. M., Horning, B. D., Paul, T. A., Ichu, T.-A., Svensson, R. U., Olucha, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.051 · Cited by 262
Krishnan, S., Miller, R. M., Tian, B., Mullins, R. D., Jacobson, M. P., & Taunton, J. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505194w · Cited by 260
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Discovery of a Potential Allosteric Ligand Binding Site in CDK2
Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R., Georg, G. I., & Schönbrunn, E. (2011) · ACS Chemical Biology · doi:10.1021/cb100410m · Cited by 188
Chohan, T., Qian, H., Pan, Y., & Chen, J.-Z. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106113633 · Cited by 185
Oxidation of thiol compounds by molecular oxygen in aqueous solutions
Bagiyan, G. A., Koroleva, I. K., Soroka, N. V., & Ufimtsev, A. V. (2003) · Russian Chemical Bulletin · doi:10.1023/a:1024761324710 · Cited by 177
A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
Kathman, S. G., Xu, Z., & Statsyuk, A. V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500345q · Cited by 170
Scaffold composition and biological relevance of screening libraries
Shelat, A. A., & Guy, R. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio0807-442 · Cited by 167
Kannan, N., & Neuwald, A. F. (2004) · Protein Science · doi:10.1110/ps.04637904 · Cited by 167
αC helix displacement as a general approach for allosteric modulation of protein kinases
Palmieri, L., & Rastelli, G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.009 · Cited by 109
Kathman, S. G., Span, I., Smith, A. T., Xu, Z., Zhan, J., Rosenzweig, A. C., & Statsyuk, A. V. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b06839 · Cited by 104
Engel, J., Lategahn, J., & Rauh, D. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00475 · Cited by 101
Schmidt, M. F., Isidro‐Llobet, A., Lisurek, M., El‐Dahshan, A., Tan, J., Hilgenfeld, R., & Rademann, J. (2008) · Angewandte Chemie International Edition · doi:10.1002/anie.200704594 · Cited by 73
Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2
Rastelli, G., Anighoro, A., Chripková, M., Carrassa, L., & Broggini, M. (2014) · Cell Cycle · doi:10.4161/cc.29295 · Cited by 56
Schmidt, M. F., El‐Dahshan, A., Keller, S., & Rademann, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200901647 · Cited by 50
Kinetic Template‐Guided Tethering of Fragments
Nonoo, R. H., Armstrong, A., & Mann, D. J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200404 · Cited by 47
Self-citationIsom, D. G., Marguet, P., Oas, T. G., & Hellinga, H. W. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22932 · Cited by 40
Comparative studies of thiol-sensitive fluorogenic probes for HAT assays
Gao, T., Yang, C., & Zheng, Y. G. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6522-5 · Cited by 39
Becker, D., Kaczmarska, Z., Arkona, C., Schulz, R., Tauber, C., Wolber, G., Hilgenfeld, R., Coll, M., & Rademann, J. (2016) · Nature Communications · doi:10.1038/ncomms12761 · Cited by 38
Yang, Y., & Guan, X. (2014) · Analytical Chemistry · doi:10.1021/ac503411p · Cited by 35
A Competitive Fluorescence Assay to Measure the Reactivity of Compounds
Epps, D. E. V., & Taylor, B. M. (2001) · Analytical Biochemistry · doi:10.1006/abio.2001.5173 · Cited by 32
Schmidt, M. F., Isidro‐Llobet, A., Lisurek, M., El‐Dahshan, A., Tan, J., Hilgenfeld, R., & Rademann, J. (2008) · Angewandte Chemie · doi:10.1002/ange.200704594 · Cited by 31
Schmidt, M. F., El‐Dahshan, A., Keller, S., & Rademann, J. (2009) · Angewandte Chemie · doi:10.1002/ange.200901647 · Cited by 19
Cited by
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
Resnick, E., Bradley, A., Gan, J., Douangamath, A., Krojer, T., Sethi, R., Geurink, P. P., Aimon, A., Amitai, G., Bellini, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b02822 · Cited by 335
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)
Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G., & de Dios, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126637 · Cited by 194
10 Years Into the Resurgence of Covalent Drugs
De Vita, E. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 122
Characterising covalent warhead reactivity
Martin, J. S., MacKenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 125
Metadata
- Authors
- Craven, G. B., Affron, D. P., Allen, C. E., Matthies, S., Greener, J. G., Morgan, R. M. L., Tate, E. W., Armstrong, A., & Mann, D. J.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Mann, David J.
- ORCID
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2018-03-26
- Volume
- 57
- Issue
- 19
- Pages
- 5257-5261
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- PMC
- PMC5947712
- OpenAlex
- W2791999156
- Cited by
- 73
- References
- 32
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 9 · 2023: 3 · 2022: 11 · 2021: 12 · 2020: 15 · 2019: 7 · 2018: 3
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Angewandte Chemie International Edition (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Imperial College Research Computing Service Data Repository
- Funders
- Engineering and Physical Sciences Research Council (EP/F500416/1)
- Biotechnology and Biological Sciences Research Council (BB/J014575/1)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- kinetic selectivity, CDK2, allosteric kinase inhibitors, chemical probes, high-throughput screening
- MeSH terms
- Cysteine, Kinetics, Ligands, Molecular Structure, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 2, Small Molecule Libraries, Drug Discovery, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.